Matinas BioPharma Holdings Inc (NYSEAMERICAN:MTNB) said Thursday that it has started a feasibility appraisal with Roche’s biotechnology subsidiary Genentech for developing oral formulations using the company’s lipid nano-crystal (LNC) platform delivery technology, which allows the development of a range of difficult-to-deliver molecules.
Bedminster, New Jersey-based Matinas is working on the advancement of its proprietary LNC platform technology for the safe delivery of therapies previously limited by toxicity or bioavailability issues. The technology is aimed at solving complex challenges relating to the safe and effective delivery of potent medicines.
“We are pleased to announce our third agreement with a large biopharmaceutical company during 2019 under which we have been asked to pair our LNC platform delivery technology with molecules which could potentially have a significant impact on disease burden,” said Matinas BioPharma CEO Jerry Jabbour.
The Matinas boss said the company continued to establish relationships with some of the most well-respected companies in the world to expand the “depth, breadth and utilization” of its unique LNC platform.
“The interest shown by these companies in applying our platform delivery technology to their compounds is indicative of the emerging importance of drug delivery in the advancement of medicine,” said Jabbour.
Benefits of LNC platform delivery technology
The company’s LNC platform delivery technology offers an intracellular drug delivery solution with potential advantages across a broad range of therapeutics.
It has demonstrated in preclinical animal models the ability to formulate and thereby re-design a wide variety of molecules and drugs including peptides, proteins, vaccines, and small molecules which require delivery technology to improve the stability of molecules inside and outside of the body; benefit from efficient delivery and cellular uptake by target cells; are currently only available in intravenous formulations, or otherwise experience significant toxicity-related adverse events.
Matinas BioPharma Holdings is a clinical-stage biopharmaceutical company focused on the development of its lead product candidate MAT9001 for the treatment of cardiovascular and metabolic conditions.
In addition, Matinas is developing MAT2203, an oral-delivered formulation of Amphotericin-B, to treat serious invasive fungal infections. The drug is based on the company’s LNC platform and has the potential to substantially improve an otherwise challenging safety profile in critically ill patients.
Contact the author Uttara Choudhury at firstname.lastname@example.org
Follow her on Twitter: @UttaraProactive